The American College of Cardiology (ACC) is preparing for its 75th annual conference, next month. From March 28 through March 30, in New Orleans, Louisiana, the ACC is hosting the American College of Cardiology 75th Annual Scientific Session and Expo. The three-day event is packed with hundreds of educational and insightful sessions on topics related to cardiovascular care. 

Today, we have a preview of sessions related to pulmonary vascular disease for all three days of the conference. Dates and times are accurate as of February 23, 2026, but consult the official conference planner for the most up to date information. Session details, beyond the title and time, are currently embargoed.

Saturday, March 28
  • Myocardial Infarction and Pulmonary Hypertension: Do Age and Gender Shape Mortality Trends in Unexpected Ways?
    • 9:30 AM – 10:30 AM
  • Sex-Based Differences in Clinical Characteristics and Phenotypes of Pulmonary Hypertension in a Diverse Urban Cohort
    • 9:30 AM – 10:30 AM
  • Trends and Hospital Outcomes in Catheter-Directed Therapy for Pulmonary Embolism: Embolectomy vs.. Thrombolysis in the United States 2016-2022
    • 11:12 AM – 11:19 AM
  • Safety and Feasibility of Exercise Stress Testing and Other Maneuvers Using Cardiac Magnetic Resonance in Subjects With Pulmonary Hypertension
    • 11:36 AM – 11:43 AM
  • Impact of the Pulmonary Index of Microcirculatory Resistance in Pulmonary Arterial Hypertension
    • 11:48 AM – 11:55 AM
  • Outcomes of Pericardiocentesis in Pulmonary Arterial Hypertension: A Systematic Review of Safety and Clinical Implications
    • 12:30 PM – 1:30 PM
  • Cannabis Use and Risk of Pulmonary Embolism in Young Adults: A 20-Year Trinetx Cohort Analysis
    • 12:30 PM – 1:30 PM
  • Early and High-Dose Treprostinil Therapy Targeting Pressure to Improve Right Ventricular Function in Pulmonary Arterial Hypertension: Artisan Interim Analysis
    • 1:05 PM – 1:12 PM
  • Pressure Matters: The Essential Role of Right Heart Catheterization for PH
    • 1:45 PM – 1:53 PM
  • Personalizing Treatment in Pulmonary Hypertension: From Guidelines to Clinical Action
    • 1:56 PM – 2:04 PM
  • Thrombo-Inflammatory Markers As Predictors of Right Ventricular Dysfunction and Hospital Length of Stay in Acute Pulmonary Embolism
    • 2:00 PM – 2:07 PM
  • Randomized Controlled Trial of Electronic Alert-Based Computerized Decision Support to Increase Detection of Chronic Thromboembolic Pulmonary Hypertension (CTEPH-DETECT)
    • 2:24 PM – 2:31 PM
  • GLP1 Agonists in Patients with Diabetes: Evaluating Incident Pulmonary Hypertension with Real World Data
    • 2:00 PM – 3:00 PM
  • Rate and Rhythm Control Strategies for Atrial Fibrillation Management in Patients with Pulmonary Arterial Hypertension
    • 3:30 PM – 4:30 PM
  • Disparities in Pulmonary Arterial Hypertension Across U.S. Regions, Sex, and Age: Insights from GBD 2021
    • 3:30 PM – 4:30 PM
Sunday, March 29
  • SGLT2 Inhibitors and Hospitalization Rates in Patients with Pulmonary Arterial Hypertension
    • 9:30 AM – 10:30 AM
  • Safety of Inhaled Nitric Oxide During Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Disease: A Large Single-Center Experience
    • 11:00 AM – 12:00 PM
  • Turning Up the Pressure: Fireside Roundtable with the PH Leaders
    • 12:15 PM – 1:15 PM
  • Comprehensive Bioinformatic Analysis Identifies M6A Methylation as a Key Mediator Linking Immunity to Idiopathic Pulmonary Arterial Hypertension
    • 12:42 PM – 12:49 PM
  • Prognostic Value of Absolute Versus Changes in Pulmonary Vascular Resistance as Predictors of European Society of Cardiology/European Resipratory Society Risk Change in Pulmonary Arterial Hypertension
    • 1:18 PM – 1:25 PM
  • Impact of Sotatercept on Functional and Hemodynamic Outcomes in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
    • 12:30 PM – 1:30 PM
  • Comparative Effectiveness of Riociguat Versus Sildenafil in Exercise Induced Pulmonary Hypertension: A Single-Center Retrospective Study
    • 2:00 PM – 3:00 PM
  • Winrevair in Pulmonary Hypertension: Real-World Adverse Events Versus Stellar Trial Experience
    • 3:30 PM – 4:30 PM
  • National Mortality Trends in Pulmonary Vascular Disease and Heart Failure: A Retrospective Analysis of CDC Wonder Data, 1999-2023
    • 3:30 PM – 4:30 PM
Monday, March 30
  • Predictive Value of Multiple Inflammatory Biomarkers for Functional Limitation at Three Months Post-Acute Pulmonary Embolism
    • 9:30 AM – 10:30 AM
  • Pulmonary Endarterectomy vs. Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: Propensity Matched Analysis of Five-Year Outcomes
    • 9:30 AM – 10:30 AM
  • Pulmonary Embolism Mortality in the United States, 1968-2023: Long-Horizon Trends, Disparities, and Forecasts to 2043
    • 11:00 AM – 11:07 AM
  • Mechanism of Mortality in Patients with Intermediate-High and High-Risk Pulmonary Emboli: A Multicenter Analysis of a Contemporary Cohort
    • 11:36 AM – 11:43 AM
  • Tricuspid Regurgitation Velocity and the Risk of Atrial Fibrillation: A 10-Year Prognostic Study in Pulmonary Arterial Hypertension
    • 11:00 AM – 12:00 PM
  • Racial and Ethnic Trends in Age-Adjusted Pulmonary Embolism Mortality in the United States: A Jointpoint Regression Analysis, 1999-2020
  • 11:00 AM – 12:00 PM
  • The Algorithm Will See You Now: AI and the Future of PH Clinical Trials
    • 12:49 PM – 1:00 PM
  • Electrocardiogram-Based Artificial Intelligence for Early Detection of Pulmonary Hypertension: A Systematic Review and Meta-Analysis
    • 12:30 PM – 1:30 PM
  • Disparities in Access to Mechanical Thrombectomy for Pulmonary Embolism Between Rural and Urban Hospitals: Insights from a National Analysis
    • 12:30 PM – 1:30 PM

Sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.

Copyright © 2026 Guideline Central, all rights reserved.